Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-ALS: VTx-002 in Amyotrophic Lateral Sclerosis
NCT07287397Phase 2Recruiting
- Sponsor
- VectorY Therapeutics
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of tamuzimod in amyotrophic lateral sclerosis (ALS), sponsored by VectorY Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
tamuzimod
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07287397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287397.